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of fibrosis were not (P> 0.05). Risk of developing HCCwas significantly
greater in patients with high WFAþ-M2BP levels (1.8) (adjusted
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Abstract: Wisteria floribunda agglutinin-positive human Mac-2
binding protein (WFAþ-M2BP) is a serologic marker correspond-
ing with degree of hepatic fibrosis. We evaluated its accuracy in
assessing hepatic fibrosis and in predicting the risk of developing
hepatocellular carcinoma (HCC) in patients with chronic hepatitis
B (CHB).
In a 5-year period (2009–2013), a total of 95 CHB patients with
available serum WFAþ-M2BP assay and transient elastography
assessment [to assess liver stiffness (LS)] who had undergone liver
biopsy were recruited for retrospective analysis.
Areas under the receiver operating characteristic curve for predicting
fibrosis stages via serumWFAþ-M2BP levelwere as follows:F2, 0.688;
F3, 0.694; and F4, 0.704 (all P< 0.05). During the follow-up period
(median, 45 months), HCC developed in 7 patients (7.4%). In patients
with HCC, age, use of antiviral therapy, test parameters (HBV DNA,
WFAþ-M2BP, and LS determinations), and histologic stage of fibrosis
were all significantly greater than in those free of HCC, whereas platelet
count was significantly lower (all P< 0.05). On multivariate analysis,
WFAþ-M2BP was found independently predictive of emergent HCC
[hazard ratio (HR)¼ 2.375; P¼ 0.036], although LS and histologic stageMD, PhD, Young N , PhD,
MD, and Hyon-Suk Kim, MD, PhD
significantly higher in patients with high (vs. low) levels ofWFAþ-M2BP
(log-rank test, P¼ 0.016).
WFAþ-M2BP determination significantly reflected degree/extent of
hepatic fibrosis and independently predicted the risk of developing HCC
in patients with CHB.
(Medicine 95(14):e3328)
Abbreviations: AFP = alpha-fetoprotein, ALT = alanine
aminotransferase, APRI = aspartate aminotransferase-to-platelet
ratio, ARFI = acoustic radiation force impulse, AUC = area under
receiver operating characteristic curve, CHB = chronic hepatitis B,
CI = confidence interval, COI = cut-off index, CT = computed
tomography, ELF = enhanced liver fibrosis, FT = FibroTest,
HBeAg = hepatitis B e antigen, HBV = hepatitis B virus, HCC =
hepatocellular carcinoma, HCV = hepatitis C virus, HR = hazard
ratio, IQR = interquartile range, kPa = kilopascals, LB = liver
biopsy, LS = liver stiffness, MRI = magnetic resonance imaging,
NPV = negative predictive value, PPV = positive predictive value,
TE = transient elastography, WFAþ-M2BP = Wisteria floribunda
agglutinin-positive human Mac-2 binding protein, YLBB = Yonsei
Liver Blood Bank.
INTRODUCTION
W orldwide, it is estimated that 2 billion people beeninfected (past or present) with hepatitis B virus (HBV),
and in 240 million, the infections are chronic.1 The clinical
spectrumofHBVinfectionvaries fromsubclinical inactivecarrier
state to progressive chronic hepatitis, culminating in cirrhosis,
decompensation, and hepatocellular carcinoma (HCC).2 HBV
infection constitutes the most frequent cause of mortality from
cirrhosis and HCC, compared with any other viral and nonviral
infection of liver, accounting for >780,000 deaths annually.3
During the past decade, new potent antiviral agents for
chronic hepatitis B (CHB) viral infections have significantly
prevented disease progression and reduced the risk of devel-
oping HCC.4 In addition, there is evidence that HBV-induced
hepatic fibrosis can be reversed by prolonged antiviral
therapy.5–7 Nevertheless, advanced fibrosis or cirrhosis still
remains the single-most important marker of poor long-term
prognosis, including emergence of HCC.8 Hence, gauging the
degree of hepatic fibrosis is still an essential element in design-
ing individualized surveillance strategies to detect HBV-related
HCC in this era of antiviral treatment.9
To date, liver biopsy (LB) remains the gold standard for
evaluating extent of hepatic fibrosis.10 However, LB is expens-, and is subject to procedural compli-
, bleeding, perforation, and even death.
error and interpretational variability are
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acknowledged as potential limitations.11 A number of nonin-
vasive surrogate methods subsequently have been devised to
surmount these shortcomings. Physical tests, such as transient
elastography (TE) and acoustic radiation force impulse (ARFI),
and serologic markers, including FibroTest (FT), enhanced liver
fibrosis (ELF) panel, and aspartate aminotransferase-to-platelet
ratio (APRI), are currently advocated as alternatives to LB.12
More recently, a glycan-based immunoassay has been
introduced, targeting WFAþ-M2BP as a biomarker for non-
invasive gauging of hepatic fibrosis.13 Briefly, M2BP is
secreted from many cell types, including hepatocytes, and its
fluctuations during N-glycosylation mirror the progression of
liver disease.13 Results of a recent study by Toshima et al14
indicate that WFAþ-M2BP serum levels accurately reflect
degrees of hepatic fibrosis, with an area under the receiver
operating characteristic curve (AUC) of 0.812 in determining an
advanced histologic stage (F 3). Another recent longitudinal
follow-up study by Yamasaki et al15 disclosed a significant
association between serum WFAþ-M2BP level and the risk of
emergent HCC in the context of chronic hepatitis C viral
infection. In addition, WFAþ-M2BP is reported to be a reliable
marker of hepatic fibrosis and prognosis in patients with
primary biliary cirrhosis and nonalcoholic fatty liver dis-
ease.16,17
Because serum WFAþ-M2BP has performed reliably as a
noninvasive biomarker in other chronic liver diseases, this
single-center, retrospective cohort study was conducted to
evaluate its accuracy in gauging hepatic fibrosis and in




In a 5-year period (2009–2013), 95 CHB patients with
available stored serum sample at the time of LB and TE were
eligible for this study. CHB was defined as persistence of serum
HBV surface antigen for >6 months and HBV DNA-positivity
by polymerase chain reaction assay. With written informed
consent, serum samples taken at LB and TE were stored in
the Yonsei Liver Blood Bank (YLBB) system (approval number,
4-2009-0725). The biopsies were done to assess severity of
hepatic fibrosis and intensity of inflammation before starting
antiviral therapy.
Exclusion criteria were as follows: LSmeasurement failure
(valid shot¼ 0); invalid LS value; existing HCC at enrollment
(or history thereof); HCC development within 6 months after
enrollment; history of antiviral therapy, decompensated cirrho-
sis, or past/present cancers other than HCC; Child–Pugh class B
or C at enrollment; LB unsuitable for proper interpretation;
stored serum sample unsatisfactory for WFAþ-M2BP assay;
and coinfection with hepatitis C virus (HCV) or HIV.
This study was performed in accordance with ethical
guidelines of the 1975 Declaration of Helsinki and approved
by the Institutional Review Board of Severance Hospital. Given
its retrospective nature, written informed consent was not
required to access clinical data.
Histologic Evaluation
LB specimens were fixed in formalin, processed routinely,
Heo et aland embedded in paraffin. Standard hematoxylin and eosin
(H&E) and trichrome (Masson) stains were then performed,
using 4-mm sections. All liver tissue samples were evaluated by
2 | www.md-journal.coman experienced pathologist blinded to patient clinical data,
including TE results and serum WFAþ-M2BP levels. Liver
histology was scored semi-quantitatively, according to Batts
and Ludwig criteria.18 Fibrosis was staged (0–4) as follows: F0,
no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis
and few septa; F3, numerous septa without cirrhosis; and
F4, cirrhosis.
Measurement of Serum WFAR-M2BP
Serum WFAþ-M2BP was quantified by lectin-Ab sand-
wich immunoassay, using a fully automated immunoanalyzer
(HISCL-2000i; Sysmex Co, Hyogo, Japan).19 Measured analyte
levels, conjugated to Wisteria floribunda agglutinin, were
indexed using the following equation:
Cutoff indexðCOIÞ ¼ ð½WFA1þM2BPsample
 ½WFA1þM2BPNCÞ=ð½WFA1þM2BPPCÞ
 ½WFA1þM2BPNC
where [WFA1þ-M2BP]sample is WFAþ-M2BP level in
serum, PC is positive control, and NC is negative control. The
positive control was supplied as a calibration solution prelimi-
narily standardized to yield a cut-off index (COI) of 1.0.19
LS Measurement by TE
Patients underwent TE at the time of enrollment by a well-
trained technician. Both technique and examination procedure
have been mentioned in previous literatures.20–23 Results were
expressed as kilopascals (kPa). Interquartile range (IQR), as an
index of intrinsic LS variability by definition, corresponded with
the LS determinant interval containing 50% of valid procure-
ments between 25th and 75th percentiles. Only LS values with a
minimum 10 validated measurements and a 60% success rate
were reliably included in this study. The median of successfully
measured values was presumed representative of LS in a given
patient only at IQR-to-median value ratios (IQR/M) of <0.3.
Baseline Workup and Follow-Up
Enrollment baseline was the date of LB and TE procure-
ment. At enrollment, all patients were evaluated to confirm the
absence of HCC using ultrasonography and laboratory tests,
including alpha-fetoprotein (AFP). If a given patient had HCC
at enrollment, the patient was excluded for this study. After
enrollment, all patients were followed up at every 3- to 6- month
intervals for HCC surveillance and screening for liver-related
complications. Diagnosis of HCC was based on guidelines
proposed by the Korea Liver Cancer Study Group.24 Accord-
ingly, a patient having 1 or more risk factors (hepatitis B or C
viral infection, cirrhosis), with either serum AFP >400 ng/mL
and positive findings on at least 1 of 3 customary imaging
studies [dynamic computed tomography (CT), dynamic mag-
netic resonance imaging (MRI), or hepatic angiography] or
serum AFP <400 ng/mL and positive findings on at least 2 of 3
imaging studies, was considered positive for HCC. On dynamic
CT or MRI, increased arterial enhancement followed by dimin-
ished enhancement relative liver (washout) in portal or equi-
librium phase was the diagnostic hallmark of HCC.
Statistical Analysis
Medicine  Volume 95, Number 14, April 2016All data were expressed as median (IQR) or n (%), where
indicated. Student t test (or Mann–Whitney test) and Chi-
squared test (or Fisher’s exact test) were utilized to examine
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the statistical significance of differences among continuous and
categorical variables. The accuracy of determinants (WFAþ-
M2BP or LS) in depicting degree of liver fibrosis was indicated
by the area under receiver operating characteristics curve
(AUC), coupled with a 95% confidence interval (CI). Cutpoints
were determined to maximize the sum of sensitivity and speci-
ficity from receiver operating characteristic curve analyses and
corresponding diagnostic indices were calculated. The DeLong
method was used to compare AUC values of WFAþ-M2BP and
LS. For longitudinal analysis, patients were censored at time of
HCC detection or at last follow-up. Cumulative HCC incidence
rates were estimated via Kaplan–Meier method and compared
using log-rank test. Independent risk factors for HCC develop-
ment were identified by univariate and subsequent multivariate
Cox regression analyses. Hazard ratios (HRs) and correspond-
ing 95% CIs were calculated. All statistical analyses relied on
standard software (SPSS v18.0; SPSS Inc, Chicago, IL), with
P value <0.05 considered statistically significant.
RESULTS
Patient Characteristics
On the basis of our exclusion criteria, 95 patients with
CHB were recruited for study, all previously undergoing LB,
TE, and serum WFAþ-M2BP assay. Baseline characteristics of
the patient population are summarized in Table 1. Median age
was 51 (IQR, 44–60) years; 69 patients (72.6%) were men; and
78 patients (82.1%) received antiviral therapy at enrollment or
during follow-up. Median values of alanine aminotransferase
Medicine  Volume 95, Number 14, April 2016(ALT), serum albumin, total bilirubin, platelet count were 41
(IQR, 28–66) IU/L, 4.2 (IQR, 3.9–4.4) g/dL, 0.7 (IQR, 0.6–
0.9) mg/dL, and 171 (IQR, 135–220) 109/L, respectively. Fifty-
TABLE 1. Baseline Characteristics (n¼95)
Variables Values
Demographic data
Age, y 51 (44–60)
Male gender 69 (72.6)




Alanine aminotransferase, IU/L 41 (28–66)
Serum albumin, g/dL 4.2 (3.9–4.4)
Total bilirubin, mg/dL 0.7 (0.6–0.9)
Platelet count, 109/L 171 (135–220)
HBeAg positivity 51 (53.7)
HBV DNA >105 copies/mL 63 (66.3)
Alpha-fetoprotein, ng/mL 3.6 (2.3–6.1)
Noninvasive fibrosis marker
WFAþ-M2BP 1.18 (0.90–1.76)
Liver stiffness, kPa 9.8 (6.9–14.0)
Histological fibrosis stage
F0–1/F2/F3/F4 16 (16.8)/29 (30.5)/10
(10.6)/40 (42.1)
F0–3/F4 55 (57.9)/40 (42.1)
Spleen diameter, cm 9.8 (8.8–11.3)
Variables are expressed as median (interquartile range) or n (%).
HBeAg¼ hepatitis B e antigen, kPa¼ kilopascal, WFAþ-M2BP¼
Wisteria floribunda agglutinin-positive Mac-2-binding protein.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.one patients (53.7%) tested positive for HBV e antigen
(HBeAg), and in 63 patients (66.3%), HBV DNA levels were
>105copies/mL.
Median WFAþ-M2BP and LS values were 1.18 (IQR,
0.9–1.76) and 9.8 (IQR, 6.9–14.0) kPa, respectively. In study
participants, histological fibrosis staging was as follows: F1, 16
(16.8%); F2, 29 (30.5%); F3, 10 (10.6%), and F4, 40 (42.1%).
Diagnostic Test Performance (WFAR-M2BP
and LS)
Performances of WFAþ-M2BP, LS, and their combi-
nations are summarized in Table 2. The AUC values for
WFAþ-M2BP in predicting fibrosis stage F2, F3, and F4
were 0.688 (95% CI, 0.539–0.836), 0.694 (95% CI, 0.589–
0.798), and 0.704 (95% CI, 0.599–0.810), respectively (all
P<0.05). Optimal cutpoints were 0.8 for F2 [sensitivity,
87.3%; specificity, 43.8%; positive predictive value (PPV),
80.0%; negative predictive value (NPV), 41.2%], 1.6 for
F3 (sensitivity, 36.0%; specificity, 88.9%; PPV, 78.3%;
NPV, 55.6%), and 2.0 for F4 (sensitivity, 35.0%; specificity,
92.7%; PPV, 77.8%; NPV, 66.2%).
With respect to LS, AUC values were 0.823 (95% CI,
0.737–0.910), 0.863 (95% CI, 0.789–0.937), and 0.848 (95%
CI, 0.766–0.930), respectively. Optimal cutpoints were 8.5 kPa
for F2 (sensitivity, 70.9%; specificity, 87.5%; PPV, 96.6%;
NPV, 37.8%), 9.5 kPa for F3 (sensitivity, 82.0%; specificity,
82.2%; PPV, 83.7%; NPV, 80.4%), and 11.0 kPa for F4 (sen-
sitivity, 70.0%; specificity, 82.3%; PPV, 80.0%; NPV, 80.0%).
In terms of accuracy, LS was significantly superior to
WFAþ-M2BP in predicting stages F3 and F4 stage (both
P<0.05), although stages F2 were similarly predicted
(P¼0.141). The accuracy of combining WFAþ-M2BP and
LS was similar to that of LS in predicting all fibrosis stages
(all P>0.05) (Table 2).
Comparison of Baseline Characteristics in
Patients With and Without HCC
Baseline characteristics of patients with and without HCC
are summarized in Table 3. Age (median, 62 vs. 51 years),
proportionate use of antiviral therapy (100 vs. 74.7%), HBV
DNA level >105 copies/mL (100.0 vs. 58.9%), serum WFAþ-
M2BP level (median, 2.2 vs. 1.1), LS value (median, 16.8 vs.
8.9 kPa), and proportion with F4 stage fibrosis (85.7 vs. 35.8%)
were significantly greater in patients who developed HCC, than
those who did not (all P<0.05), whereas platelet count (median
133 vs. 177 109/L) was significantly lower by comparison
(P<0.05).
Factors Associated With HCC Development
To prevent statistical colinearity, WFAþ-M2BP, LS, and
histologic stage of fibrosis were incorporated into respective
multivariate analyses (Table 4). Platelet count, WFAþ-M2BP,
LS, and fibrosis stage displayed significance in univariate
analysis (all P<0.05). However, WFAþ-M2BP (after adjust-
ment) emerged as the sole independent predictor of developing
HCC (HR¼ 2.375, 95% CI 1.056–5.340; P¼0.036),
with platelet count showing borderline statistical significance
(P¼0.059). With adjustment of platelet count and LS,
platelet count did show statistical significance (HR¼ 0.972,
95% CI 0.947–0.997; P¼0.031), whereas LS was borderline
Mac-2 Binding Protein in Chronic Hepatitis B Infection(P¼0.065). Only platelet count proved significant
(HR¼ 0.971, 95%CI 0.946–0.997; P¼0.027) with adjustment
of fibrosis stage.
www.md-journal.com | 3















F2 LS 0.823 (0.737–0.910) 8.5 kPa 70.9 87.5 96.6 37.8 —
WFAþ-M2BP 0.688 (0.539–0.836) 0.8 87.3 43.8 80.0 41.2 0.141
WFAþ-M2BP þ LS 0.836 (0.754–0.917) 9.0 76.0 81.3 95.2 40.6 0.362
WFAþ-M2BPLS 0.816 (0.709–0.923) 7.0 87.3 56.2 90.8 47.3 0.891
F3 LS 0.863 (0.789–0.937) 9.5 kPa 82.0 82.2 83.7 80.4 —
WFAþ-M2BP 0.694 (0.589–0.798) 1.6 36.0 88.9 78.3 55.6 0.006
WFAþ-M2BP þ LS 0.877 (0.807–0.946) 11.0 80.0 84.4 85.1 79.2 0.176
WFAþ-M2BPLS 0.835 (0.756–0.915) 9.8 86.0 64.4 72.9 80.6 0.420
F4 LS 0.848 (0.766–0.930) 11.0 kPa 70.0 82.3 80.0 80.0 —
WFAþ-M2BP 0.704 (0.599–0.810) 2.0 35.0 92.7 77.8 66.2 0.028
WFAþ-M2BP þ LS 0.865 (0.790–0.940) 11.5 78.8 77.4 65.0 87.3 0.142
WFAþ-M2BPLS 0.827 (0.746–0.909) 25.0 90.9 72.6 50.0 96.4 0.586
onfi
gglu
Heo et al Medicine  Volume 95, Number 14, April 2016Relative Risk of Developing HCC With Binary
Stratification
Table 5 summarizes the relative risk of developing HCC in
binary stratified subsets. Due to small sample size and no
instances of HCC among patients with serum levels of
WFAþ-M2BP less than median value (1.18), the third quartile
value of 1.80 served as cutpoint of WFAþ-M2BP levels in
binary stratification, thus calculating the relative risk of emer-
gent HCC in patients with high (vs. low) WFAþ-M2BP levels.
Of the 2 groups, assigned by serumWFAþ-M2BP levels (<1.80
vs. 1.80), the subset with high levels (1.80) showed signifi-
cantly greater risk of developing HCC by comparison
AUC¼ area under the receiver operating characteristic curve, CI¼ c
PPV¼ positive predictive value, WFAþ-M2BP¼Wisteria floribunda a(HR¼ 12.8, 95% CI 1.5–107.0; P¼0.019). Cumulative inci-
dence rates of HCC were also significantly higher in patients
with high (vs. low) levels ofWFAþ-M2BP (P¼0.016, log-rank
TABLE 3. Comparison Between Patients With and Without HCC
Variables With HCC
Demographic data
Age, y 62 (5
Male gender 6 (8
Antiviral therapy at enrollment or during follow-up 7 (1
Laboratory data
Alanine aminotransferase, IU/L 40 (3
Serum albumin, g/dL 4.0 (3
Total bilirubin, mg/dL 0.6 (0
Platelet count, 109/L 133 (1
HBeAg positivity 6 (8
HBV DNA >105 copies/mL 7 (1
Alpha-fetoprotein, ng/mL 8.9 (4
Noninvasive fibrosis marker
WFAþ-M2BP 2.2 (1
Liver stiffness, (kPa 16.8 (1
Histological fibrosis stage
F0–3/F4 1 (1
Variables are expressed as median (interquartile range) or n (%).
HBeAg¼ hepatitis B e antigen, HCC¼ hepatocellular carcinoma, kPa¼ k
2-binding protein.
4 | www.md-journal.comtest) (Figure 1). With adjustment of platelet count, the higher
relative risk of patients with high levels of WFAþ-M2BP was
maintained (HR¼ 1.5, 95% CI 1.4–97.2; P¼ 0.025). In com-
paring risk at F4 stage fibrosis with risk at lesser stages (F0-F3),
statistical significance was not reached (all P> 0.05).
DISCUSSION
In this era of potent HBV antiviral therapy, the burden of
fibrosis is considered the single-most important risk factor for
developing HCC due to HBV infection.8 Because tissue sam-
plings for evaluating fibrosis are not always feasible, various
noninvasive physical and biochemical tests (i.e., TE, ARFI, FT,
dence interval, LS¼ liver stiffness, NPV¼ negative predictive value,
tinin-positive Mac-2-binding protein.ELF, and APRI) have been developed. Recently, M2BP, a
protein involved in cell adhesion, was found to vary in quality
and quantity during progressive fibrosis.25,26 Activation of
Development
(n¼ 7, 7.4%) Without HCC (n¼ 88, 92.6%) P
5–63) 51 (43–59) 0.038
5.7) 63 (66.3) 0.378
00) 71 (74.7) <0.001
8–51) 41 (28–67) 0.526
.6–4.2) 4.2 (3.9–4.4) 0.113
.5–1.2) 0.7 (0.6–0.9) 0.915
23–150) 177 (137–226) 0.027
5.7) 45 (47.4) 0.054
00) 56 (58.9) <0.001
.1–14.6) 3.4 (2.2–5.4) 0.233
.7–3.9) 1.1 (0.8–1.5) 0.031
4.3–21.1) 8.9 (6.7–11.8) 0.001
4.3)/6 (85.7) 54 (64.2)/34 (35.8) 0.015
ilopascal, WFAþ-M2BP¼Wisteria floribunda agglutinin-positive Mac-
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.









P P HR (95% CI) P HR (95% CI) P HR (95% CI)
Age, y 0.054
Male gender 0.433
Antiviral therapy at enrollment
or during follow-up
0.998
Alanine aminotransferase, IU/L 0.563
Serum albumin, g/dL 0.118
Total bilirubin, mg/dL 0.914
Platelet count, 109/L 0.033 0.059 0.976 (0.952–1.001) 0.031 0.972 (0.947–0.997) 0.027 0.971 (0.946–0.997)
HBeAg positivity 0.113
HBV DNA >105 copies/mL 0.998
Alpha-fetoprotein, ng/mL 0.271
WFAþ-M2BP 0.001 0.036 2.375 (1.056–5.340) — — — —
Liver stiffness, kPa 0.004 — — 0.065 1.119 (0.993–1.260) — —
F0–3/F4 0.041 — — — 0.387 2.879 (0.263–31.536)
Spleen diameter, cm 0.456
CI¼ confidence interval, HBeAg¼ hepatitis B e antigen, HCC¼ hepatocellular carcinoma, HR¼ hazard ratio, kPa¼ kilopascal, LS¼ liver
e M
Medicine  Volume 95, Number 14, April 2016 Mac-2 Binding Protein in Chronic Hepatitis B Infectionhepatic stellate cells and reversal of such activation may
coincide with shifts in WFAþ-M2BP levels.27 However, it is
apparent that WFAþ-M2BP more specifically reflects the pro-
gression of fibrosis and thus is a suitable novel surrogate for LB
in chronic liver diseases.19,28
In this study, the diagnostic accuracy of serum WFAþ-
M2BP assay at specified stages of fibrosis seemed unsatisfac-
tory (AUC 0.7: F2, 0.688, F3, 0.694; F4, 0.704); and
compared with LS determination, the diagnostic accuracy of
serum WFAþ-M2BP level in predicting stages F3 or F4 stage
was significantly inferior (both P<0.05), despite similarity in
predicting stages F2 (P¼0.141). However, as the extent of
fibrosis increased, specificity rose from 43.8 to 92.7%, implying
that WFAþ-M2BP may be useful in detecting advanced fibrosis
or cirrhosis, regardless of the inferiority displayed overall. From
a longitudinal perspective, serum WFAþ-M2BP levels (similar
to LS value) were significantly higher in patients prone to
development of HCC, as opposed to those who were not
(median, 2.2 vs. 1.1; P¼ 0.031). Furthermore, measured serum
stiffness, M2BP¼WFAþ-M2BP, Wisteria floribunda agglutinin-positivWFAþ-M2BP proved independently predictive of HCC devel-
opment (HR¼ 2.375), whereas histologic staging of fibrosis did
not (P> 0.05). Finally, by stratifying the study population into 2
TABLE 5. Relative Risk of HCC Development According to Binary
Markers Risk Groups HR (95% CI)
WFAþ-M2BP Low (<1.8) 1 (reference)
High (>1.8) 12.8 (1.5–107.0)
Histology F0–3 1 (reference)
F4 7.5 (1.05–63.0)

Adjusted HR was calculated by adjusting platelet count.
CI¼ confidence interval, HCC¼ hepatocellular carcinoma, HR¼ hazard
binding protein.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.groups, based on a cutpoint of 1.8 for the WFAþ-M2BP marker,
a significantly greater risk (adjusted HR¼ 11.5) of developing
HCC at high (vs. low) levels of WFAþ-M2BP was evident. For
these reasons, serum WFAþ-M2BP level may reasonably be
used to assess risk of developing HCC in patients with CHB.
Our study has several strong points. Although past efforts
have documented the accuracy of WFAþ-M2BP assay in
patients with chronic liver diseases of other etiologies, none
has yet addressed HBV. In HCV infection, for instance, AUC
values reported by stage of fibrosis were 0.83 (F2) and 0.74
(F3),29 and in primary biliary cirrhosis, AUC values cited
were 0.979 (F2), 0.933 (F3), and 0.965 (F4).17 A significant
association between WFAþ-M2BP level and fibrotic burden
was also established in patients with nonalcoholic fatty liver
disease (AUC: 0.876, F2; 0.879, F3).16 Moreover, in auto-
immune hepatitis, the AUC ofWFAþ-M2BP in predicting stage
F4 fibrosis was 0.853, exceeding that of other serologic fibrosis
markers, including FIB-4 index and hyaluronic acid.30 Thus,
our findings offer a basis for future large-scale validation
ac-2-binding protein.studies directed at HBV.
Through TE examination, we also pursued LS in the context





— 1 (reference) —
0.019 11.5 (1.4–97.2) 0.025
— 1 (reference) —
0.062 4.7 (0.5–42.0) 0.165
ratio, WFAþ-M2BP¼Wisteria floribunda agglutinin-positive Mac-2-
www.md-journal.com | 5
sectional analysis. Further large-scale study is warranted to
FIGURE 1. Cumulative rates of HCC in 2-tier stratification of
serum WFAþ-M2BP levels (Kaplan–Meier plot). Risk increased
þ
Heo et alaccuracy relative to serum WFAþ-M2BP.20,22,23,31–34 In our
cross-sectional analysis, LS value showed accuracy similar to
that encountered in prior studies (AUC: 0.823–0.848),23,35
suggesting that even with the limited size of this cohort, patient
characteristics were appropriate for evaluating WFAþ-M2BP
as well. However, the diagnostic accuracy of WFAþ-M2BP
(AUC0.7) proved unsatisfactory, compared with other studies
(AUC >0.8). Reasons for this are unclear but may in part be
explained by inherent properties of HBV, in that background
fibrosis often fluctuates during the course of disease.36 On the
contrary, HCV, primary biliary cirrhosis, and autoimmune
hepatitis are more insidious in nature, resulting in slowly pro-
gressive fibrosis.37,38 Probably due to this unsatisfactory
accuracy of M2BP, the combination of WFAþ-M2BP and LS
could not enhance the overall accuracy in predicting all fibrosis
stages in comparison to LS (all P>0.05). Apart from cross-
sectional analysis, which appeared unsatisfactory, we similarly
explored the prognostic value of WFAþ-M2BP from a longi-
tudinal aspect. Serum WFAþ-M2BP levels proved significantly
predictive in terms of risk involved in developing HCC. Previous
studies likewise have concluded that serumWFAþ-M2BP levels
may reflect pre-cancer status or hepatocellular carcinogenesis,
rather than a product of existing HCC,39 and are predictive of
HCC arising in patients chronically infected with HCV.15,39,40
Consequently, a prospective large-scale study should be con-
ducted to validate our results, however questionable the cross-
sectional analysis.
We are also aware of several unresolved issues in our
study. First, our sample size was small, and instances of HCC
were few. Furthermore, longitudinal analysis of LS indicated
only borderline statistical significance in assessing the risk of
developing HCC (P¼0.065), despite notable similarity to
significantly with corresponding increase in WFA -M2BP levels
between groups (P¼0.016, log-rank test).previous TE-based investigations (AUC >0.8).23,35 Given that
LS value is a known factor in predicting the risk of HCC,21,31,32
this seemingly inconsistent outcome may be related to the
6 | www.md-journal.comlimited sampling. Sample size was also inadequate to system-
atically control relevant variables, such as antiviral agent use,
existing cirrhosis, and necroinflammatory activity, for subgroup
analyses, even though the appropriate adjustments were made in
multivariate analyses. In addition, only binary stratification of
the study population was feasible, rather than a detailed step-
wise delineation according to WFAþ-M2BP level, thus deter-
mining relative risks among subgroups. Larger populations are
needed to substantiate present findings. Another issue is that our
serologic cutpoints for WFAþ-M2BP differed from those of
prior studies [0.8 (F2) vs. 0.90–1.86; 1.6 (F3) vs. 0.94–
2.21; 2.0 (F4) vs. 1.46–2.64]. However, this was not the case
with cutpoints determined for LS values (confirmed by other
publications),14,16,17,29 so it is possible that disease etiology, and
not sample size, is pivotal in arriving at thresholds of WFAþ-
M2BP. Still, an optimal cutpoint for serum WFAþ-M2BP
awaits investigation in terms of HBV. Finally, we found it
difficult to investigate whether WFAþ-M2BP is useful for
dynamic monitoring of HCC risk, detecting changes in fibrotic
burden during prolonged antiviral treatment. Only baseline
serum WFAþ-M2BP levels were available. Because it is vir-
tually impossible to serially sample the liver in routine practice,
serial WFAþ-M2BP assays may affirm the prognostic utility of
this approach, a matter for future studies.
In conclusion, our study disclosed an independent longi-
tudinal association between serum WFAþ-M2BP level and the
risk of emergent HCC in patients with CHB, despite its unsa-
tisfactory performance in gauging fibrotic burden on cross-
Medicine  Volume 95, Number 14, April 2016validate the prognostic role of WFAþ-M2BP during clinical
surveillance of such patients.
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